LEXINGTON, Mass., Oct. 15 /PRNewswire/ -- Synta Pharmaceuticals Corp., an
emerging pharmaceutical company, today announced the following appointments:
Ninad Deshpanday, Ph.D. as Vice President, Drug Product Development; Patricia
McCall as Vice President, Human Resources; and Cynthia Clayton as Director,
Investor Relations and Corporate Communications.
Ninad Deshpanday, Ph.D., Vice President, Drug Product Development
Dr. Deshpanday comes to Synta from Cardinal Health where he was the
Technical Business Director responsible for both business development and
strategic technical functions within the Pharmaceutics division. Dr.
Deshpanday has over 14 years' experience in product development and drug
delivery technology and has led the product development efforts behind
numerous successful filings with regulatory agencies in the U.S., Europe, and
Japan, across multiple therapeutic areas including dermatology, cardiology,
and cancer. Prior to Cardinal Health, Dr. Deshpanday held positions at
aaiPharma, TheraTech, Inc., and Procter & Gamble Pharmaceuticals. Dr.
Deshpanday received both his B.S. and Masters in Pharmacy from Gujarat
University in India, and his Ph.D. in Pharmacy from the University of South
"We have made significant progress over the past year advancing our
clinical pipeline," said Keizo Koya, Ph.D., Senior Vice President, Drug
Development at Synta. "Ninad's expertise in manufacturing, formulation, and
product development, and his experience with multiple investigational new drug
submissions and new drug applications will be invaluable to Synta as we
continue to advance our pipeline to commercial readiness."
Patricia McCall, Vice President, Human Resources
Ms. McCall brings to Synta nearly 25 years' experience as a human
resources executive. Most recently, Ms. McCall held the position of Vice
President, Human Resources for ACMI Corporation, a 1,000-employee medical
device firm, where she led the human resource related efforts to transform
that organization into a growth company. Ms. McCall also served as
International Human Resource Director for Energia Global International. Prior
to that, Ms. McCall spent 19 years with Hewlett-Packard's Healthcare Solutions
Group in areas of increasing responsibility including Human Resources
Director. Ms. McCall received her B.S. in Business Administration from
Emmanuel College in Boston.
"Tricia joins our team at a crucial time in Synta's growth," said Safi
Bahcall, Ph.D., President and Chief Executive Officer of Synta. "Her extensive
experience in all aspects of strategic and operational human resources
management will be important as we transition from a discovery-focused and
early clinical operation, to a fully integrated, commercial drug development
company. Tricia will lead the effort to preserve the spirit of our core
values and guiding principles as we grow -- our focus on quality of science,
speed of execution, and passion for improving the lives of patients. In
addition, she will be continuing our mission of attracting and developing the
world-class talent and expertise we need to achieve our goals."
Cynthia Clayton, Director, Investor Relations and Corporate Communications
Ms. Clayton joins Synta from Millennium Pharmaceuticals where she was the
Senior Manager, Investor and Corporate Communications. At Millennium, she
worked as part of an award-winning team driving the communications initiatives
of an established, product-driven biopharmaceutical company. Prior to joining
Millennium, Ms. Clayton served as Manager, Corporate Communications for Curis,
an earlier-stage biotechnology company that underwent a three-way merger to
emerge as a public company. Ms. Clayton earned her B.A. in Communications
from the University of Hartford in Connecticut.
"This is a very exciting and critical time for Synta as we continue to
grow and add key functions company-wide," said John McCarthy, Senior Vice
President, Corporate Development and Chief Financial Officer at Synta.
"Cynthia's combined set of experiences will be an important asset to the team
as we begin to reach out to the audiences interested in learning more about
Synta's differentiated business strategy, exciting and diverse clinical
programs, and compelling career opportunities."
Synta Pharmaceuticals is an emerging pharmaceutical company focused on
discovering, developing, and commercializing products for extending and
enhancing the lives of patients with severe medical conditions. Synta has a
diverse pipeline of first-in-class, small-molecule drug candidates for the
treatment of major immune disorders and cancers, with two lead products in
multiple Phase 2 clinical trials. All clinical candidates were developed
internally, and Synta fully owns all rights in all indications and markets.
Synta developed as a buyout of the U.S. subsidiary of a large Japanese
pharmaceutical company in 2002 and, as a result, has an experienced and
fully integrated drug discovery and development operation. Synta has raised
over $128 million in private financing in the last three years to support its
plans. For more information, please see http://www.syntapharma.com.
Synta Pharmaceuticals Corp. Euro RSCG Life NRP
Cynthia Clayton Robert Stanislaro
Director, Investor Relations Senior Account Executive
and Corporate Communications (212) 845-4268
(781) 541-7125 email@example.com
SOURCE Synta Pharmaceuticals Corp.